AU2011233401B2 - ECT2 peptides and vaccines including the same - Google Patents

ECT2 peptides and vaccines including the same Download PDF

Info

Publication number
AU2011233401B2
AU2011233401B2 AU2011233401A AU2011233401A AU2011233401B2 AU 2011233401 B2 AU2011233401 B2 AU 2011233401B2 AU 2011233401 A AU2011233401 A AU 2011233401A AU 2011233401 A AU2011233401 A AU 2011233401A AU 2011233401 B2 AU2011233401 B2 AU 2011233401B2
Authority
AU
Australia
Prior art keywords
peptide
cancer
present
peptides
ect2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011233401A
Other languages
English (en)
Other versions
AU2011233401A1 (en
Inventor
Yusuke Nakamura
Ryuji Ohsawa
Takuya Tsunoda
Tomohisa Watanabe
Sachiko Yoshimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of AU2011233401A1 publication Critical patent/AU2011233401A1/en
Application granted granted Critical
Publication of AU2011233401B2 publication Critical patent/AU2011233401B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011233401A 2010-04-02 2011-03-30 ECT2 peptides and vaccines including the same Ceased AU2011233401B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32057710P 2010-04-02 2010-04-02
US61/320,577 2010-04-02
PCT/JP2011/001909 WO2011122022A1 (en) 2010-04-02 2011-03-30 Ect2 peptides and vaccines including the same

Publications (2)

Publication Number Publication Date
AU2011233401A1 AU2011233401A1 (en) 2012-10-25
AU2011233401B2 true AU2011233401B2 (en) 2015-03-26

Family

ID=44711777

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011233401A Ceased AU2011233401B2 (en) 2010-04-02 2011-03-30 ECT2 peptides and vaccines including the same

Country Status (20)

Country Link
US (1) US8951975B2 (enExample)
EP (1) EP2553096B1 (enExample)
JP (1) JP5816965B2 (enExample)
KR (1) KR101863557B1 (enExample)
CN (1) CN102939379B (enExample)
AR (1) AR081065A1 (enExample)
AU (1) AU2011233401B2 (enExample)
BR (1) BR112012024997B1 (enExample)
CA (1) CA2795318C (enExample)
CO (1) CO6571869A2 (enExample)
DK (1) DK2553096T3 (enExample)
EA (1) EA027940B1 (enExample)
ES (1) ES2655437T3 (enExample)
IL (1) IL222057A (enExample)
MX (1) MX342000B (enExample)
NZ (1) NZ603379A (enExample)
SG (1) SG184165A1 (enExample)
TW (2) TWI538685B (enExample)
WO (1) WO2011122022A1 (enExample)
ZA (1) ZA201207342B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
GB201517538D0 (en) * 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
PH12022551111A1 (en) 2015-10-05 2023-08-23 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007150077A2 (en) * 2006-06-23 2007-12-27 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2008102557A1 (en) * 2007-02-21 2008-08-28 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing tumor-associated antigens

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
EP0841945B1 (en) 1995-08-03 2006-03-08 Rijksuniversiteit te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
EP1332153A4 (en) * 2000-10-12 2006-01-11 Exelixis Inc HUMAN ECT2 AND METHOD OF USE THEREOF
US7227007B2 (en) * 2000-12-28 2007-06-05 Asahi Kasei Pharma Corporation NF-κB activating gene
EP2336167B1 (en) 2001-03-14 2019-05-29 Dako Denmark A/S MHC molecule constructs and their uses for diagnosis and therapy
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
WO2002096943A1 (en) * 2001-05-25 2002-12-05 Asahi Kasei Kabushiki Kaisha Stat6-activating genes
US20030092616A1 (en) 2001-05-25 2003-05-15 Akio Matsuda STAT6 activation gene
WO2002099062A2 (en) 2001-06-04 2002-12-12 Curagen Corporation Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
CA2447935A1 (en) * 2001-06-04 2002-12-12 Curagen Corporation Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP4614952B2 (ja) 2003-08-20 2011-01-19 オンコセラピー・サイエンス株式会社 腎細胞癌（ｒｃｃ）の潜在的な新規治療標的としての低酸素誘導タンパク質２（ｈｉｇ２）
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
US7998695B2 (en) 2005-02-10 2011-08-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
EP1907582B1 (en) 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 as a therapeutic target for esophageal cancer
EP2305811A1 (en) 2005-07-27 2011-04-06 Oncotherapy Science, Inc. Method of diagnosing smal cell lung cancer
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
CN101432022A (zh) * 2006-02-28 2009-05-13 肿瘤疗法科学股份有限公司 利用抗-EphA4抗体效应物作用损伤细胞的方法
AU2007311946A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
JP5378795B2 (ja) 2006-10-20 2013-12-25 中外製薬株式会社 抗ｈｂ−ｅｇｆ抗体を有効成分として含む医薬組成物
EP2105511A1 (en) 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
WO2010007791A1 (en) * 2008-07-16 2010-01-21 Oncotherapy Science, Inc. Ect2 oncogene as a therapeutic target and prognostic indicator for lung and esophageal cancer
TW201008574A (en) * 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007150077A2 (en) * 2006-06-23 2007-12-27 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2008102557A1 (en) * 2007-02-21 2008-08-28 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing tumor-associated antigens

Also Published As

Publication number Publication date
DK2553096T3 (en) 2018-01-15
IL222057A (en) 2017-12-31
TWI538685B (zh) 2016-06-21
SG184165A1 (en) 2012-10-30
TW201138803A (en) 2011-11-16
EP2553096A1 (en) 2013-02-06
JP2013523082A (ja) 2013-06-17
NZ603379A (en) 2014-09-26
BR112012024997B1 (pt) 2022-03-22
KR101863557B1 (ko) 2018-06-01
EP2553096B1 (en) 2017-11-22
CO6571869A2 (es) 2012-11-30
ES2655437T3 (es) 2018-02-20
MX342000B (es) 2016-09-09
AR081065A1 (es) 2012-06-06
BR112012024997A2 (pt) 2017-05-23
US8951975B2 (en) 2015-02-10
CA2795318A1 (en) 2011-10-06
CA2795318C (en) 2018-11-13
JP5816965B2 (ja) 2015-11-18
EA027940B1 (ru) 2017-09-29
KR20130033367A (ko) 2013-04-03
EP2553096A4 (en) 2013-11-13
WO2011122022A1 (en) 2011-10-06
TW201627003A (zh) 2016-08-01
CN102939379A (zh) 2013-02-20
ZA201207342B (en) 2013-06-26
US20130095128A1 (en) 2013-04-18
AU2011233401A1 (en) 2012-10-25
CN102939379B (zh) 2016-08-03
EA201291004A1 (ru) 2013-04-30
MX2012011385A (es) 2013-12-16

Similar Documents

Publication Publication Date Title
WO2011125334A1 (en) Cdca5 peptides and vaccines including the same
AU2012265677A1 (en) SEMA5B peptides and vaccines including the same
US20170198010A1 (en) Tomm34 peptides and vaccines including the same
US20160368958A1 (en) Hjurp peptides and vaccines including the same
US20120135020A1 (en) Ttk peptides and vaccines including the same
US8951975B2 (en) ECT2 peptides and vaccines including the same
WO2011074236A1 (en) Tmem22 peptides and vaccines including the same
AU2011300253A1 (en) TTLL4 peptides and vaccines containing the same
WO2014087626A1 (en) Sema5b peptides and vaccines containing the same
US20130287805A1 (en) C18orf54 peptides and vaccines including the same
AU2011319359A1 (en) WDHD1 peptides and vaccines including the same
WO2011125139A1 (en) Cluap1 peptides and vaccines including the same
WO2012032763A1 (en) Vangl1 peptides and vaccines including the same
HK1180003B (en) Ect2 peptides and vaccines including the same
HK1180003A (en) Ect2 peptides and vaccines including the same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired